Adaptive Design, Often Maligned
Add bookmark
Adaptive Design, Often Maligned
Add bookmark
When carried out well, adaptive trials not only provide evidence of safety and efficacy more quickly, but also allow you to assess that evidence and get answers earlier. In this interview John Johnson, Senior Biostatistician at Cato Research, speaks to Andrea Charles from Pharma IQ, about the three key strategies for effective use of adaptive trials in drug development and the implementation hurdles small pharma and biotech companies face.
[inlinead]
Tags:
John Johnson
Clinical Trials
clinical design
clinical analysis
clinical reporting
adaptive trials
adaptive methods
Bayesian statistics
clinical trials process
adaptive trial elements
statistical standardisation
biostatistics
adaptive design
